Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;7(Suppl 8):S388.
doi: 10.21037/atm.2019.12.86.

The cost and benefit of anti-TNF therapy from a population perspective-for what it's worth

Joseph D Frasca  1 , Adam S Cheifetz  2
Affiliations
Editorial

The cost and benefit of anti-TNF therapy from a population perspective-for what it's worth

Joseph D Frasca et al. Ann Transl Med. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: AS Cheifetz: Consulting: Janssen, Abbvie, Takeda, Pfizer, Samsung, Arena, Bacainn, EMD Serono, Arsanis, Grifols, Prometheus; Research support: Inform Diagnostics. The other author has no conflicts of interest to declare.

Comment on

References

    1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s disease cA2 Study Group. N Engl J Med 1997;337:1029-35. 10.1056/NEJM199710093371502 - DOI - PubMed
    1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. 10.1016/S0140-6736(02)08512-4 - DOI - PubMed
    1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. 10.1056/NEJMoa050516 - DOI - PubMed
    1. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876-85. 10.1056/NEJMoa030815 - DOI - PubMed
    1. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65.e1-3. 10.1053/j.gastro.2011.10.032 - DOI - PubMed